Diabetes Metab J. 2024;48(2):253-264.

Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients.

, , ,

제1저자 박영환 · 교신저자 임수

PMID 38273791 PMC10995484 DOI 10.4093/dmj.2023.0128 IF 8.2 내분비대사내과

소속 (1)

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Abstract

BACKGRUOUND We investigated the long-term efficacy and safety of initial triple therapy using metformin, a dipeptidyl peptidase-4 inhibitor, and a sodium-glucose cotransporter-2 inhibitor, in patients with type 2 diabetes mellitus.

METHODS We enrolled 170 drug-naïve patients with glycosylated hemoglobin (HbA1c) level >7.5% who had started triple therapy (metformin, sitagliptin, and empagliflozin). Glycemic, metabolic, and urinary parameters were measured for 24 months.

RESULTS After 24 months, HbA1c level decreased significantly from 11.0%±1.8% to 7.0%±1.7%. At 12 and 24 months, the rates of achievement of the glycemic target goal (HbA1c <7.0%) were 72.5% and 61.7%, respectively, and homeostasis model assessment of β-cell function and insulin resistance indices improved. Whole-body fat percentage decreased by 1.08%, and whole-body muscle percentage increased by 0.97% after 24 months. Fatty liver indices and albuminuria improved significantly. The concentration of ketone bodies was elevated at the baseline but decreased after 24 months. There were no serious adverse events, including ketoacidosis.

CONCLUSION Initial triple combination therapy with metformin, sitagliptin, and empagliflozin led to achievement of the glycemic target goal, which was maintained for 24 months without severe hypoglycemia but with improved metabolic function and albuminuria. This combination therapy may be a good strategy for drug-naïve patients with type 2 diabetes mellitus.

Keywords

Dipeptidyl-peptidase IV inhibitorsGlycated hemoglobinSodium-glucose transporter 2 inhibitors

Figures

**Fig. 1.** Parameters related to glycemic control over the 24 months. Values are presented as mean±standard deviation. (A) Glycosylated hemoglobin (HbA1c) level. (B) Fasting plasma glucose concentration. (C) Postload 2-hour glucose levels. (D) Fasting insulin levels. (E) Homeostasis model assessment of insulin resistance (HOMA-IR). (F) Homeostasis model assessment of β-cell function (HOMA-β). ^aP<0.05: paired t-test between the baseline and after treatment.

**Fig. 2.** Body weight, body mass index (BMI), muscle mass, fat mass, and muscle and fat percentages over the 24 months. Values are presented as mean±standard deviation. (A) Body weight. (B) BMI. (C) Total muscle and fat mass. (E) Total muscle and fat percentages. ^aP<0.05: paired t-test between the values recorded at the baseline and after treatment.

**Fig. 3.** Changes in the concentrations of ketone bodies, glucagon, and free fatty acids over the 24 months. Values are presented as mean±standard deviation. Logarithmically transformed values were used for comparisons of the concentrations of fasting glucagon, total ketone bodies, β-hydroxybutyrate, and acetoacetate. (A) Total ketone bodies. (B) β-Hydroxybutyrate. (C) Acetoacetate. (D) Glucagon. (E) Free fatty acids. ^aP<0.05: paired t-test between the values recorded at the baseline and after treatment.

**Fig. 4.** Renal and liver functional indexes over the 24 months. Values are presented as mean±standard deviation. (A) Serum creatinine (Cr) concentration. (B) Estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration equation (eGFR-CKD-EPI). (C) Urinary protein/Cr and urinary albumin/Cr ratios at 0, 12, and 24 months. (D) Aspartate aminotransferase (AST). (E) Alanine aminotransferase (ALT). (F) Prevalence of nonalcoholic fatty liver disease (NAFLD) based on the NAFLD fatty liver score at 0, 12, and 24 months. ^aP<0.05: paired t-test between the values recorded at the baseline and after treatment.

그림 출처: PubMed Central 공개 논문 (PMC10995484)

Comment · 정정

Conflict of interest statement

CONFLICTS OF INTEREST . No potential conflict of interest relevant to this article was reported.

그 밖의 정보

출판 형태: Journal Article, Research Support, Non-U.S. Gov't
저널: Diabetes & metabolism journal · eISSN 2233-6087
전자 출판: 2024-01-26
MeSH: Humans · Diabetes Mellitus, Type 2* / metabolism · Metformin* / adverse effects · Sitagliptin Phosphate / adverse effects · Glycated Hemoglobin · Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use · Albuminuria · Blood Glucose / metabolism · Treatment Outcome · Benzhydryl Compounds* · Glucosides*
Substances: Metformin · Sitagliptin Phosphate · empagliflozin · Glycated Hemoglobin · Sodium-Glucose Transporter 2 Inhibitors · Blood Glucose · Benzhydryl Compounds · Glucosides
연구비: Seoul National University Bundang Hospital
참고문헌: 43편